Search results
Showing 376 to 390 of 489 results for 2011
NICE has developed a medtech innovation briefing (MIB) on Thora 3Di for assessing asthma in children .
NICE has developed a medtech innovation briefing (MIB) on CytoSorb therapy for sepsis .
Discontinued Reference number: GID-TAG400
This quality standard covers the care of pregnant women or pregnant people who are considering having or may need to have a caesarean birth, including those who have had a caesarean birth in the past. It includes decision making, reducing the risk of complications and care after a caesarean birth. It describes high-quality care in priority areas for improvement.
View quality statements for QS32Show all sections
Sections for QS32
- Quality statements
- Quality statement 1: Vaginal birth after a caesarean birth
- Quality statement 2: Request for a caesarean birth: maternity team involvement
- Quality statement 3: Request for a caesarean birth: anxiety
- Quality statement 4: Consultant obstetrician involvement in decision making for planned caesarean birth
- Quality statement 5: Timing of planned caesarean birth
- Quality statement 6: Consultant obstetrician involvement in decision making for unplanned caesarean birth
- Quality statement 7: The use of fetal blood sampling
Discontinued Reference number: GID-TAG426
This guideline covers improving oral health by developing and implementing a strategy that meets the needs of people in the local community. It aims to promote and protect people’s oral health by improving their diet and oral hygiene, and by encouraging them to visit the dentist regularly.
Ridaforolimus for the maintenance treatment of metastatic soft tissue or bone sarcoma [ID415]
Discontinued Reference number: GID-TAG431
Bone metastases (hormone refractory prostate cancer) - denosumab [ID405]
Discontinued Reference number: GID-TAG300
Everolimus for the treatment of prophylaxis of organ rejection in cardiac transplantation [ID114]
Discontinued Reference number: GID-TAG232
Multiple myeloma (one prior therapy) - vorinostat (with bortezomib) [ID501]
Discontinued Reference number: GID-TAG435
This quality standard covers preventing and controlling infection in adults, young people and children receiving healthcare in primary, community and secondary care settings. It includes preventing healthcare-associated infections that develop because of treatment or from being in a healthcare setting. It describes high-quality care in priority areas for improvement.
View quality statements for QS61Show all sections
Sections for QS61
- Quality statements
- Quality statement 1: Antimicrobial stewardship
- Quality statement 2: Organisational responsibility
- Quality statement 3: Hand decontamination
- Quality statement 4: Urinary catheters
- Quality statement 5: Vascular access devices
- Quality statement 6: Educating people about infection prevention and control
- Update information
Evidence-based recommendations on darolutamide (Nubeqa) for treating hormone-relapsed prostate cancer in adults at high risk of developing metastatic disease.
Evidence-based recommendations on ramucirumab (Cyramza) for treating advanced gastric cancer or gastro-oesophageal junction adenocarcinoma previously treated with chemotherapy.
Cabozantinib for previously treated advanced renal cell carcinoma (TA463)
Evidence-based recommendations on cabozantinib (Cabometyx) for previously treated advance renal cell carcinoma in adults.
Tivozanib for treating advanced renal cell carcinoma (TA512)
Evidence-based recommendations on tivozanib (Fotivda) for treating advanced renal cell carcinoma in adults.